Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 INCPF | Healthcare | $1.60 | 0.00 | $2.27B | 12.83 | ― | Strong Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| INCPF | InnoCare Pharma Ltd. | 1.60 | -0.88 | -35.50% |
| Name | Price | % Change | |
|---|---|---|---|
| INCPF | $1.60 | -35.50% |
DBS analyst Mark Kong CFA reiterated a Buy rating on InnoCare Pharma Ltd. today and set a price target of HK$18.30. Mark Kong CFA has given his Buy rating due
InnoCare Pharma Ltd. ( ($HK:9969) ) has shared an announcement. InnoCare Pharma Limited has issued its unaudited third-quarter 2026 report, prepared under People’s Republic of China accounting principles to meet
InnoCare Pharma Ltd. ( ($HK:9969) ) has shared an update. InnoCare Pharma Limited has scheduled a board meeting for 26 October 2026 to review and approve its unaudited third‑quarter results
InnoCare Pharma Ltd. ( ($HK:9969) ) has provided an announcement. InnoCare Pharma has entered into a strategic research collaboration and license agreement with global pharmaceutical major Eli Lilly and Company
InnoCare Pharma Ltd. (($HK:9969)) has held its Q2 earnings call. Read on for the main highlights of the call. InnoCare Pharma’s latest earnings call struck a decidedly upbeat tone, as
InnoCare Pharma Ltd. ( ($HK:9969) ) has provided an announcement. InnoCare Pharma reported a sharp increase in interim revenue, with total income rising 55.5% to RMB1,137.1 million in the six
InnoCare Pharma Ltd. ( ($HK:9969) ) has shared an announcement. InnoCare Pharma Limited has scheduled a board meeting for 24 August 2026 to review and approve the interim results for
InnoCare Pharma Ltd. ( ($HK:9969) ) has shared an update. InnoCare Pharma announced that its Phase III registrational trial of fadeucravacitinib (ICP‑488) in adults with moderate‑to‑severe plaque psoriasis met its
InnoCare Pharma Ltd. ( ($HK:9969) ) has issued an announcement. InnoCare Pharma reported positive topline data from the Phase II portion of its ongoing Phase II/III adaptive trial of soficitinib
InnoCare Pharma Ltd. ( ($HK:9969) ) has shared an announcement. InnoCare Pharma announced that its Phase III registrational trial of soficitinib, an internally developed next-generation oral TYK2 inhibitor, in adults
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| INCPF | Apr 1, 2027TBA | $2.27B | $0.04 | $249.23M | -0.13 | 12.83 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
